2023 Approvals

FDA Greenlights Agamree for Duchenne Muscular Dystrophy on October 26, 2023

FDA Greenlights Agamree for Duchenne Muscular Dystrophy on October 26, 2023

What is Agamree prescribed for?   Agamree is prescribed for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. What is Agamree and what does it do? Agamree,  pronounced ah gam' ree, (generic name: vamorolone), is a medication that was approved by the FDA to help treat Duchenne muscular dystrophy (DMD).  DMD...

FDA Approves Bimzelx for Plaque Psoriasis: A New Hope for Patients as of October 17, 2023

FDA Approves Bimzelx for Plaque Psoriasis: A New Hope for Patients as of October 17, 2023

What is Bimzelx prescribed for?  Bimzelx is prescribed to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. What is Bimzelx and what does it do? Bimzelx, pronounced bim zel’ ex, (generic name: bimekizumab-bkzx) is a medication approved by the FDA to help adults with moderate to severe plaque...

FDA Approves Zilbrysq for Myasthenia Gravis on October 17, 2023

FDA Approves Zilbrysq for Myasthenia Gravis on October 17, 2023

What is Zilbrysq prescribed for?   Zilbrysq is prescribed to treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive. What is Zilbrysq and what does it do? Zilbrysq, pronounced zIL-brisk, (generic name: zilucoplan) is a new medication approved by the FDA for treating adults with a condition called...

FDA Approves Velsipity for Ulcerative Colitis Treatment on October 13, 2023

FDA Approves Velsipity for Ulcerative Colitis Treatment on October 13, 2023

What is Velsipity prescribed for?  Velsipity is prescribed to treat moderately to severely active ulcerative colitis in adults. What is the name of the drug and what does it do? Velsipity, pronounced Vel-sip-itee, (generic name: etrasimod) is a new medication approved by the FDA to treat adults with moderately to severely active ulcerative colitis, a form of...

FDA Approves Rivfloza for Late-Onset Pompe Disease on September 28, 2023

FDA Approves Rivfloza for Late-Onset Pompe Disease on September 28, 2023

What is Rivfloza prescribed for?   Rivfloza is used to treat Late-Onset Pompe Disease, a rare condition where the body can't break down sugar properly due to a missing enzyme. This causes sugar to build up in the muscles, leading to muscle weakness and breathing problems. Rivfloza helps by replacing the missing enzyme, making it easier for the body to...

FDA Approves DAYBUE for Treating Rett Syndrome Symptoms on March 10, 2023

FDA Approves DAYBUE for Treating Rett Syndrome Symptoms on March 10, 2023

What is DAYBUE prescribed for?   DAYBUE (generic name: trofinetide), pronounced “day-BYOO,” is indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older. What is the name of the drug and what does it do?  DAYBUE is used to treat Rett syndrome in adults and children who are 2 years old or older.  Rett...